FIELD: chemistry.
SUBSTANCE: group of inventions relates to a method for separating H2L3 antibodies from an antibody composition containing H2L3 antibodies and H2L2 antibodies, and this method includes: (i) applying the antibody composition to a cation exchange resin so that the H2L3 antibodies and H2L2 antibodies bind to the resin, and the composition of antibodies has a pH of less than 6.0; (ii) applying the composition for elution with a salt concentration from 300 mm to 600 mm on a cation exchange resin; and (iii) collecting a composition containing H2L2 antibodies eluted from the resin, the said composition containing H2L2 antibodies containing one or more eluted column volumes selected from column volumes 1–9, as well as a method for separating anti-CD123 H2L3 antibodies from an anti-CD123 antibody composition comprising an anti-CD123 antibody H2L3 and an anti-CD123 antibody H2L2, wherein the anti-CD123 antibody H2L3 and anti-CD123 antibody H2L2 comprise the following: (i) heavy chain variable region CDR1, CDR2 and CDR3 sequences of SEQ ID NO: 5–7, respectively, and the sequences of CDR1, CDR2, and CDR3 of the light chain variable region of SEQ ID NO: 8–10, respectively, and (ii) an IgG heavy chain constant domain.
EFFECT: separation of H2L3 antibodies from compositions containing H2L3 antibodies and H2L2 antibodies using a cation exchange resin.
47 cl, 8 dwg, 4 tbl, 3 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF PURIFICATION FOR REMOVING TYROSINE SULPHATED ANTIBODIES VARIANTS, PURIFIED COMPOSITIONS | 2017 |
|
RU2793400C2 |
METHODS OF TREATING USING ANTI-CD123 IMMUNOCONJUGATES | 2019 |
|
RU2816847C2 |
METHODS AND COMPOSITIONS INCLUDING PURIFIED RECOMBINANT POLYPEPTIDES | 2014 |
|
RU2793783C1 |
ANTI-CD123 ANTIBODIES AND CONJUGATES AND DERIVATIVES THEREOF | 2016 |
|
RU2739612C2 |
CONJUGATES OF BINDER AND ACTIVE SUBSTANCE (ADC) HAVING ENZYMATICALLY CLEAVABLE GROUPS | 2017 |
|
RU2761390C2 |
COMBINED FORMULATIONS OF ANTI-LAG3 ANTIBODY AND ANTI-PD-1 ANTIBODY | 2019 |
|
RU2822192C2 |
METHODS OF TREATING CANCER USING ANTI-PD-1 ANTIBODIES AND ANTI-CTLA4 ANTIBODIES | 2019 |
|
RU2825835C2 |
CHIMERIC ANTIGENIC (CAR) RECEPTOR AGAINST CD123 FOR USE IN TREATING MALIGNANT TUMORS | 2015 |
|
RU2724999C2 |
BINDING MOLECULES SPECIFIC TO IL-21 AND THEIR USE | 2015 |
|
RU2804456C1 |
ANTI-CLAUDIN ANTIBODIES AND USE THEREOF | 2019 |
|
RU2815926C2 |
Authors
Dates
2023-05-03—Published
2018-09-21—Filed